| Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know |
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-06 15:00:49 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil |
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline. |
zacks.com |
2025-05-02 14:05:32 |
Czytaj oryginał (ang.) |
| This Soaring Stock Just Delivered More Good News. Time to Buy? |
It's hard to find a biotech company that has performed better than Summit Therapeutics (SMMT 2.86%) in the past year. The stock is up by a whopping 512%, and it's no secret why. |
fool.com |
2025-05-02 12:30:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2025. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated. |
businesswire.com |
2025-05-01 20:09:00 |
Czytaj oryginał (ang.) |
| Why Is Summit Therapeutics Stock Trading Higher On Monday? |
Summit Therapeutics Inc. SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303. |
benzinga.com |
2025-04-28 17:00:15 |
Czytaj oryginał (ang.) |
| Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today |
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading. |
fool.com |
2025-04-25 21:05:19 |
Czytaj oryginał (ang.) |
| What's Going On With Summit Therapeutics Stock On Friday? |
Summit Therapeutics Inc SMMT stock is trading lower on Friday. |
benzinga.com |
2025-04-25 19:14:24 |
Czytaj oryginał (ang.) |
| Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o. |
businesswire.com |
2025-04-25 18:50:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summ. |
businesswire.com |
2025-04-24 20:15:00 |
Czytaj oryginał (ang.) |
| Why Is Summit Therapeutics Stock Soaring On Wednesday? |
Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. |
benzinga.com |
2025-04-23 19:47:43 |
Czytaj oryginał (ang.) |
| Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced o. |
businesswire.com |
2025-04-23 10:15:00 |
Czytaj oryginał (ang.) |
| This Company's Co-CEOs Just Bought More Shares. Should You? |
Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into the company's prospects. |
fool.com |
2025-04-23 09:45:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition |
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit's financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation. |
seekingalpha.com |
2025-04-14 13:08:20 |
Czytaj oryginał (ang.) |
| 3 Magnificent Stocks That Could Double or More by 2030 |
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential. |
fool.com |
2025-04-12 18:45:00 |
Czytaj oryginał (ang.) |
| Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets |
Shares of lung cancer-focused biotech Summit Therapeutics (SMMT 10.72%) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader markets were down significantly on the day at that time, including the SPDR S&P Biotech ETF (XBI -4.37%), which was down 4.4%. |
fool.com |
2025-04-10 20:36:00 |
Czytaj oryginał (ang.) |
| 2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade |
Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the trailing-12-month period no longer looks quite as impressive as it did at the start of 2025 -- the equity index is down nearly 1.5% over this period. |
fool.com |
2025-04-06 11:02:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Com. |
businesswire.com |
2025-04-04 20:15:00 |
Czytaj oryginał (ang.) |
| 3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months |
Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025. |
fool.com |
2025-04-03 13:45:00 |
Czytaj oryginał (ang.) |
| Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today |
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET. |
fool.com |
2025-03-31 19:25:05 |
Czytaj oryginał (ang.) |
| Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. |
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest. |
fool.com |
2025-03-31 08:53:00 |
Czytaj oryginał (ang.) |
| Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer |
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication. |
zacks.com |
2025-02-25 11:40:34 |
Czytaj oryginał (ang.) |
| Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs |
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. "Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted Bob Duggan and Dr. Maky Zanganeh, Summit's Co-CEOs. |
prnewswire.com |
2025-02-24 22:13:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program |
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program |
seekingalpha.com |
2025-02-24 17:33:03 |
Czytaj oryginał (ang.) |
| Pfizer: What The Summit Therapeutics Deal Brings |
Pfizer: What The Summit Therapeutics Deal Brings |
seekingalpha.com |
2025-02-24 12:53:50 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024 |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the fourth quarter and year-ended December 31, 2024. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects as. |
businesswire.com |
2025-02-24 08:05:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. “Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact fo. |
businesswire.com |
2025-02-24 08:00:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Trounce the Market in 2025 |
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch. |
fool.com |
2025-02-17 06:32:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ. |
businesswire.com |
2025-02-14 18:15:00 |
Czytaj oryginał (ang.) |
| Is Summit Therapeutics a Millionaire Maker? |
Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress for its leading pipeline candidate, ivonescimab, a cancer treatment in development. |
fool.com |
2025-02-09 08:15:00 |
Czytaj oryginał (ang.) |
| 2 Stocks That Could Soar Again in 2025 |
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%). |
fool.com |
2025-02-08 10:50:00 |
Czytaj oryginał (ang.) |
| Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? |
It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate, and at that point, a sell-off may ensue. |
fool.com |
2025-01-30 11:15:00 |
Czytaj oryginał (ang.) |
| 3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% |
Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how analysts view a given stock. |
fool.com |
2025-01-23 07:47:00 |
Czytaj oryginał (ang.) |
| Why Summit Therapeutics Stock Is Jumping Today |
Shares of Summit Therapeutics (SMMT 15.40%) had jumped 14.3% at 11:31 a.m. ET on Tuesday. |
fool.com |
2025-01-21 14:06:12 |
Czytaj oryginał (ang.) |
| Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) |
Summit Therapeutics' stock rose 888% since September 2023, driven by positive Phase 3 data for ivonescimab showing superior PFS vs Keytruda in NSCLC. Phase 3 HARMONi-2 trial showed 11.14 vs 5.82 months PFS benefit over Keytruda, with OS data expected in first half of 2025. Company has strong cash position ($486.9M) but faces increased burn rate with multiple Phase 3 trials ongoing. |
seekingalpha.com |
2025-01-18 11:33:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ. |
businesswire.com |
2025-01-16 18:15:00 |
Czytaj oryginał (ang.) |
| Why Summit Therapeutics Rocketed 584% in 2024 |
Shares of biotech Summit Therapeutics (SMMT -8.39%) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence. |
fool.com |
2025-01-15 11:35:00 |
Czytaj oryginał (ang.) |
| Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 |
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. |
seekingalpha.com |
2025-01-13 20:10:02 |
Czytaj oryginał (ang.) |
| Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will present a corporate overview and an update on the progress of our organization, including the d. |
businesswire.com |
2025-01-07 09:00:00 |
Czytaj oryginał (ang.) |
| Prediction: These 3 Healthcare Stocks Will Soar in 2025 |
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good. |
fool.com |
2025-01-04 08:48:00 |
Czytaj oryginał (ang.) |
| Best-Performing Stocks Of 2024 |
Best-Performing Stocks Of 2024 |
seekingalpha.com |
2025-01-03 01:46:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Be Monster Winners in 2025 |
What do many kids like most about the coming of a new year? The fireworks. |
fool.com |
2024-12-29 08:47:00 |
Czytaj oryginał (ang.) |
| Where Will Summit Therapeutics Be in 5 Years? |
Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023. |
fool.com |
2024-12-20 08:30:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Turn $1,000 into $5,000 by 2030 |
A five-bagger in only five years? Any investor would love to buy such a stock. |
fool.com |
2024-12-20 06:50:00 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Biotech Stocks to Buy With $200 Right Now |
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs. |
fool.com |
2024-12-18 07:44:00 |
Czytaj oryginał (ang.) |
| 2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street |
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (VKTX -1.75%) and Summit Therapeutics (SMMT -0.22%) more than doubled in 2024. |
fool.com |
2024-12-15 09:37:00 |
Czytaj oryginał (ang.) |
| Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today |
Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced life-changing returns in much shorter time frames. |
fool.com |
2024-12-14 18:00:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. |
businesswire.com |
2024-12-13 18:15:00 |
Czytaj oryginał (ang.) |
| Here's Why Summit Therapeutics Stock Price Rose 6% on Friday |
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug. |
zacks.com |
2024-12-09 11:15:36 |
Czytaj oryginał (ang.) |
| Why Summit Therapeutics Stock Rocketed 6% Higher on Friday |
Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session. |
fool.com |
2024-12-06 21:09:38 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial |
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are promising, but registration in the US will require completion of HARMONI-7, which has just begun recruiting. Top-line data from the HARMONi trial is expected in mid-2025, potentially leading to FDA approval with complete enrollment as of Q3. |
seekingalpha.com |
2024-12-02 16:10:07 |
Czytaj oryginał (ang.) |
| Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher |
Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to. |
fool.com |
2024-12-02 06:22:00 |
Czytaj oryginał (ang.) |
| Warning: This Skyrocketing Stock Has a Hidden Risk |
Up 860% in the last 12 months alone, Summit Therapeutics (SMMT -2.53%) is a skyrocketing stock that likely has more upside in store. |
fool.com |
2024-11-30 08:05:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics to Present at Upcoming Investor Conferences |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:4. |
businesswire.com |
2024-11-26 18:15:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks in the Making |
3 Monster Stocks in the Making |
fool.com |
2024-11-23 08:30:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. |
businesswire.com |
2024-11-21 18:15:00 |
Czytaj oryginał (ang.) |
| 2 Hot Biopharma Stocks to Buy and Hold for 5 Years |
If you're patient, these businesses have a lot of promising projects in the works. |
fool.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Why Summit Therapeutics Stock Was a Winner Today |
A cancer drug has vast potential for the company, says a pundit newly following it. |
fool.com |
2024-11-04 20:56:35 |
Czytaj oryginał (ang.) |
| Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo |
JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones. |
benzinga.com |
2024-11-04 16:14:17 |
Czytaj oryginał (ang.) |